Articles |
Rhone-Poulenc Rorer-Gencell, Cell and Gene Therapy Division, Atherosclerosis Department, Centre de recherche de Vitry-Alfortville, Vitry sur Seine (N.D., L.B., F.E., P.D.); Institut Pasteur, INSERM 325, Lille (A.T., L.P.-N., B.L., C.F., G.C., J.C.F.); and Institut National de la Recherche Agronomique, Jouy en Josas (C.V., L.M.H.), France.
Correspondence to Dr Nicolas Duverger, Atherosclerosis Department, Centre de Recherche de Vitry-Alfortville, 13, Quai Jules Guesde-BP 14, 94403 Vitry sur Seine, Cedex, France. E-mail nicolas.duverger@rp.fr.
Human apolipoprotein A-I (apo A-I) transgenic rabbits were created by use of an 11-kb genomic human apo A-I construct containing a liver-specific promoter. Five independent transgenic lines were obtained in which human apo A-I gene had integrated and was expressed. Plasma levels of human apo A-I ranged from 8 to 100 mg/dL for the founder and up to 175 mg/dL for the progeny. Rabbit apo A-I levels were substantially decreased in the transgenic rabbits. HDL cholesterol (HDL-C) levels were higher in two of the five transgenic rabbit lines than in controls (line 20 versus nontransgenic littermate, HDL-C=80±7 versus 37±6 mg/dL; line 8 versus nontransgenic littermate, HDL-C=54±16 versus 35±6 mg/dL). This resulted in less atherogenic lipoprotein profiles, with very low (VLDL+LDL-C)/HDL-C ratios. HDL size and protein and lipid compositions were similar between transgenic and littermate nontransgenic rabbits. However, a large amount of pre-ß apo A-Icontaining lipoproteins was observed in the plasma of the highest human apo A-I expressor. Cell cholesterol efflux was evaluated with the incubation of whole serum from transgenic and control rabbits. Cell cholesterol efflux was highly correlated with HDL cholesterol, with apo A-I, and with the presence of pre-ß apo A-Icontaining lipoproteins. These rabbits will be an extremely useful model for the evaluation of the effect of increased hepatic apo A-I expression on atherosclerosis.
Key Words: New Zealand White rabbit apolipoprotein A-I transgenic cholesterol lipoprotein
This article has been cited by other articles:
![]() |
V. K. Mishra, M. N. Palgunachari, N. R. Krishna, J. Glushka, J. P. Segrest, and G. M. Anantharamaiah Effect of Leucine to Phenylalanine Substitution on the Nonpolar Face of a Class A Amphipathic Helical Peptide on Its Interaction with Lipid: HIGH RESOLUTION SOLUTION NMR STUDIES OF 4F-DIMYRISTOYLPHOSPHATIDYLCHOLINE DISCOIDAL COMPLEX J. Biol. Chem., December 5, 2008; 283(49): 34393 - 34402. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Oram and J. W. Heinecke ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease Physiol Rev, October 1, 2005; 85(4): 1343 - 1372. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zabalawi, S. Bhat, T. Loughlin, M. J. Thomas, E. Alexander, M. Cline, B. Bullock, M. Willingham, and M. G. Sorci-Thomas Induction of Fatal Inflammation in LDL Receptor and ApoA-I Double-Knockout Mice Fed Dietary Fat and Cholesterol Am. J. Pathol., September 1, 2003; 163(3): 1201 - 1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Nanjee, C. J. Cooke, W. L. Olszewski, and N. E. Miller Concentrations of Electrophoretic and Size Subclasses of Apolipoprotein A-I-Containing Particles in Human Peripheral Lymph Arterioscler Thromb Vasc Biol, September 1, 2000; 20(9): 2148 - 2155. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hennuyer, P. Poulain, L. Madsen, R. K. Berge, L.-M. Houdebine, D. Branellec, J.-C. Fruchart, C. Fievet, N. Duverger, and B. Staels Beneficial Effects of Fibrates on Apolipoprotein A-I Metabolism Occur Independently of Any Peroxisome Proliferative Response Circulation, May 11, 1999; 99(18): 2445 - 2451. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Brousseau and J. M. Hoeg Transgenic rabbits as models for atherosclerosis research J. Lipid Res., March 1, 1999; 40(3): 365 - 375. [Abstract] [Full Text] |
||||
![]() |
P. M. O'Connor, B. R. Zysow, S. A. Schoenhaus, B. Y. Ishida, S. T. Kunitake, J. M. Naya-Vigne, P. N. Duchateau, R. F. Redberg, S. J. Spencer, S. Mark, et al. Prebeta-1 HDL in plasma of normolipidemic individuals: influences of plasma lipoproteins, age, and gender J. Lipid Res., March 1, 1998; 39(3): 670 - 678. [Abstract] [Full Text] |
||||
![]() |
D. Rouy, N. Duverger, S. D. Lin, F. Emmanuel, L.-M. Houdebine, P. Denefle, C. Viglietta, E. Gong, E. M. Rubin, and S. D. Hughes Apolipoprotein(a) Yeast Artificial Chromosome Transgenic Rabbits. LIPOPROTEIN(a) ASSEMBLY WITH HUMAN AND RABBIT APOLIPOPROTEIN B J. Biol. Chem., January 9, 1998; 273(2): 1247 - 1251. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stocks, M. N. Nanjee, and N. E. Miller Analysis of high density lipoprotein apolipoproteins by capillary zone and capillary SDS gel electrophoresis J. Lipid Res., January 1, 1998; 39(1): 218 - 227. [Abstract] [Full Text] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |